Status:
UNKNOWN
A NEW SCORING SYSTEM FOR PREDICTION OF PDA
Lead Sponsor:
Kanuni Sultan Suleyman Training and Research Hospital
Conditions:
Patent Ductus Arteriosus
Prematurity; Extreme
Eligibility:
All Genders
Up to 15 years
Brief Summary
Patent ductus arteriosus (PDA) is an important morbidity of that the diagnosis and treatment is controversy in premature infants. A number of scoring systems have been developed, including the finding...
Detailed Description
This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiograph...
Eligibility Criteria
Inclusion
- informed consent obtained from parents
- extremely preterm infants
- infants born before 28 gestational week
Exclusion
- lack of informed consent
- chromosomal abnormality
- cardiovascular abnormality
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 15 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04270240
Start Date
January 15 2019
End Date
February 15 2021
Last Update
May 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seda Yilmaz Semerci
Istanbul, Turkey (Türkiye), 34303